

**Key Takeaways:**

- Several treatment options for COVID-19 management in the outpatient setting have become available in the past 4-5 months.
- Our recommendations for therapeutics in order of preference: Paxlovid, Remdesivir, mAb, and Molnupiravir.
- The supply of therapeutics is increasing. There are online tools to assist with locators of treatments and drug interactions. (Example: COVID Therapeutics Locator website)
- 

**Further Reading:**

Infection Control and Prevention	NIH COVID-19 Treatment Guidelines. <a href="#">NIH website.</a>
	Clinical Care Options Infectious Disease Resources. <a href="#">Clinical Care Options website.</a>
	Gottlieb RL et. al. <i>Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.</i> N Engl J Med 2022; 386:305-315. <a href="#">New England Journal of Medicine website.</a>
	Bernal AJ et. al. <i>Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.</i> N Engl J Med 2022; 386:509-520. <a href="#">New England Journal of Medicine website.</a>
	Hammond J et. al. <i>Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.</i> N Engl J Med 2022; 386:1397-1408. <a href="#">New England Journal of Medicine website.</a>
	<a href="#">COVID-19 Drug Interactions website.</a>
	<a href="#">COVID Therapeutics Locator website.</a>